Study of 68Ga-JH12 PET/CT scan in solid tumors
Part of Cancer clinical trials.
This trial tests a new imaging agent, 68Ga-JH12, used during a PET/CT scan to see how it spreads through the body and how much radiation it gives off. It is for people with solid tumors who want to help researchers understand this better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a solid tumor that has been confirmed by a biopsy or other lab test
- You are able to give written permission to join the study
- You are not pregnant or breastfeeding
- You do not have severe liver or kidney problems
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new imaging agent called 68Ga-JH04 that is used with a PET/CT scan. The goal is to see how the agent travels through the body and how much radiation it gives off, which may help doctors better understand and treat your tumor.
This study tests whether a new imaging agent called 68Ga-MY6349 can help detect tumors during a PET/CT scan. If you are an adult with a solid tumor (newly diagnosed or already treated), you may be able to take part in this research to see if the new tracer works better than standard imaging.
This trial uses a special PET scan (68Ga-DOTA-NI-FAPI04) to get clearer images of various solid tumors. It may help doctors see your cancer better and plan your treatment.
This study tests a new PET imaging agent called [68Ga]Ga-ELI411 to help see tumors more clearly. It is for adults with solid tumors who are already scheduled for a standard PET scan, and may help doctors better understand and manage their cancer.
This study tests a new PET/CT imaging agent (gallium-68 FFD) to see how well it works in both healthy volunteers and people with solid tumors. It could help doctors find or monitor cancer more accurately.
This trial tests a new type of imaging scan that uses a special tracer to help doctors see solid tumors more clearly. The scan may help improve how tumors are detected and monitored during treatment.
Hear when a new Malignant Neoplasm trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.